ALK and non-small cell lung carcinoma: Thus, based on the existing experimental data, the EMA has approved the administration of atezolizumab combined with anti-angiogenesis drugs plus chemotherapy for the treatment of non-squamous NSCLC patients harboring the EGFR/ALK mutations who failed to respond to the first-line molecular targeted therapy.